APA (7th ed.) Citation

Dong, Z., Zhong, W., Zhang, X., Su, J., Xie, Z., Liu, S., . . . Wu, Y. (2017). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical cancer research, 23(12), 3012-3024. https://doi.org/10.1158/1078-0432.CCR-16-2554

Chicago Style (17th ed.) Citation

Dong, Zhong-Yi, et al. "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma." Clinical Cancer Research 23, no. 12 (2017): 3012-3024. https://doi.org/10.1158/1078-0432.CCR-16-2554.

MLA (9th ed.) Citation

Dong, Zhong-Yi, et al. "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma." Clinical Cancer Research, vol. 23, no. 12, 2017, pp. 3012-3024, https://doi.org/10.1158/1078-0432.CCR-16-2554.